Core Insights - Hologic reported revenue of $1.01 billion for the quarter ended March 2025, reflecting a year-over-year decline of 1.2% but exceeding the Zacks Consensus Estimate of $1 billion by 0.34% [1] - The company's EPS was $1.03, unchanged from the same quarter last year, and surpassed the consensus estimate of $1.02 by 0.98% [1] Revenue Performance by Segment - Diagnostics - Cytology and perinatal: Revenue of $118.50 million, down 1.7% year-over-year, below the average estimate of $119.94 million [4] - Diagnostics - Molecular diagnostics: Revenue of $326 million, up 1% year-over-year, slightly below the average estimate of $328.58 million [4] - Diagnostics - Blood screening: Revenue of $9.10 million, a significant increase of 31.9% year-over-year, exceeding the average estimate of $4.99 million [4] - Breast health - Breast imaging: Revenue of $271.90 million, down 11.4% year-over-year, below the average estimate of $282.58 million [4] - Skeletal health: Revenue of $33 million, up 21.8% year-over-year, surpassing the average estimate of $18 million [4] - Total Breast health: Revenue of $356.20 million, down 7.4% year-over-year, below the average estimate of $369.50 million [4] - Total Diagnostics: Revenue of $453.60 million, up 0.8% year-over-year, slightly above the average estimate of $453.52 million [4] - GYN surgical: Revenue of $162.50 million, up 4.2% year-over-year, exceeding the average estimate of $161.11 million [4] - Breast health - Interventional breast solutions: Revenue of $84.30 million, up 8.2% year-over-year, below the average estimate of $86.91 million [4] Stock Performance - Hologic's shares have returned -3.9% over the past month, compared to a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]